文献速递胸部肿瘤

STK11突变在晚期非小细胞肺癌中的临床影响

Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer.
PubMed 文献 · Eur J Cancer · 2022-06-24

这项在法国新阿基坦地区开展、为期24个月的多中心观察性研究,评估了STK11突变对晚期非小细胞肺癌患者总生存期及一线治疗失败时间的影响。结果显示,STK11突变患者的中位总生存期显著短于野生型患者(4.7个月 vs 16.2个月,P<0.001),且突变与更短的治疗失败时间显著相关。

要点

  • STK11突变患者中位OS为4.7个月,野生型为16.2个月,差异显著(P<0.001)。

核心结论

  • STK11突变的存在与NSCLC不良预后相关。
  • STK11突变患者的中位OS显著短于野生型患者(4.7个月 vs 16.2个月,Log-rank检验P<0.001)。
  • 治疗类型(化疗或免疫治疗)不影响STK11突变患者TTF缩短的幅度。

研究设计与样本

  • 观察性多中心研究,在法国新阿基坦地区开展,为期24个月。
  • 各中心收集临床、组织病理学和影像学数据,二代测序分析在波尔多大学医院进行。
  • 患者数据从NSCLC诊断日期纵向随访至删失事件(治疗失败或死亡,视情况而定)或研究结束日期。
  • 主要目标是在真实世界中评估按STK11突变状态分组的NSCLC患者总生存期。
  • 次要目标是评估一线化疗或免疫治疗的治疗失败时间(TTF)。

主要发现

  • 从首次给药起算的中位OS:STK11wt患者16.2个月(11-nr)vs STK11mut患者4.7个月(2.5-9.4),Log-rank检验P<0.001。
  • 治疗类型(化疗、免疫治疗)不影响STK11mut患者TTF缩短的幅度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mutations in STK11/LKB1 gene present a negative impact on tumour immune microenvironment, especially with concomitant activating KRAS mutation. These recent data may explain a decreased response to immunotherapy treatment in STK11 mutant non-small cell lung cancer (NSCLC). OBJECTIVE: The primary objective is to evaluate, in a real-life setting, overall survival (OS) in patients with NSCLC according to the presence of STK11 mutation. The secondary objective is to assess time to treatment failure (TTF) for the first-line chemotherapy or immunotherapy. METHODS: This observational multicentric study was conducted in Nouvelle-Aquitaine (France), for 24 months. Clinical, histopathological and imagery data were collected in each centre while the next-generation sequencing analysis was performed in Bordeaux Hospital University. Patient's data were longitudinally followed from NSCLC diagnosis date to the occurrence of censoring events (therapeutic failure or death, as applicable) or until the study end date. RESULTS: median OS from the first drug administration was significantly longer for STK11wt patients than STK11mut patients (16.2 months [11 - nr] versus 4.7 months [2.5-9.4]; Log-rank test P < 0.001). The Presence of STK11 mutation was significantly associated with shortened OS (RR = 2.26 [1.35-3.79], P = 0.002). First-line TTF was significantly shorter in STK11mut population and the presence of the mutation was significantly associated with an increase in treatment failures (RR = 1.87 [1.21-2.89], P = 0.005). The type of treatment (chemotherapy, immunotherapy) does not influence the amplitude of reduced TTF in patients with STK11mut. CONCLUSION: The presence of STK11 mutation is associated with poor prognosis in NSCLC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Rosellini P, Amintas S, Caumont C, et al. Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer. Eur J Cancer. 2022. PMID: 35759814. doi:10.1016/j.ejca.2022.05.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。